Acromegaly - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acromegaly - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Acromegaly - Pipeline Review, H1 2016', provides an overview of the Acromegaly pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects
- The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acromegaly

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acromegaly Overview 9
Therapeutics Development 10
Pipeline Products for Acromegaly - Overview 10
Pipeline Products for Acromegaly - Comparative Analysis 11
Acromegaly - Therapeutics under Development by Companies 12
Acromegaly - Therapeutics under Investigation by Universities/Institutes 13
Acromegaly - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acromegaly - Products under Development by Companies 17
Acromegaly - Products under Investigation by Universities/Institutes 18
Acromegaly - Companies Involved in Therapeutics Development 19
Aegis Therapeutics, LLC 19
Antisense Therapeutics Limited 20
Chiasma, Inc. 21
Crinetics Pharmaceuticals, Inc. 22
DexTech Medical AB 23
Foresee Pharmaceuticals, LLC 24
Glide Pharmaceutical Technologies Limited 25
Ionis Pharmaceuticals, Inc. 26
Ipsen S.A. 27
Italfarmaco S.p.A. 28
Novartis AG 29
Peptron, Inc. 30
Sompharmaceuticals S.A. 31
Strongbridge Biopharma plc 32
Acromegaly - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ATL-1103 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BIM-23A758 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
COR-005 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
FP-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
G-02113 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ISIS-GHRLRx - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ITF-2984 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
L-779976 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
octreotide acetate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
octreotide acetate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
octreotide acetate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
octreotide acetate long acting - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
octreotide acetate SR - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
octreotide SR - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pasireotide ER - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Somadex - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SXN-101742 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SXN-101959 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Acromegaly - Recent Pipeline Updates 68
Acromegaly - Dormant Projects 79
Acromegaly - Discontinued Products 80
Acromegaly - Product Development Milestones 81
Featured News & Press Releases 81
Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference 81
Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced 81
Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly 82
Aug 10, 2015: ANP Licensing Partner for ATL1103 Cortendo Files Prospectus 83
Jun 15, 2015: Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly 83
Apr 16, 2015: ATL1103 - New European Patent Application Allowance 84
Mar 06, 2015: ATL1103 Phase II Trial Data to be presented at ENDO 2015 84
Mar 05, 2015: ATL1103 Higher Dose Study to Support Phase III to Commence 85
Mar 05, 2015: Chiasma Announces New Data for Investigational Octreotide Capsules 85
Feb 09, 2015: Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly 87
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Acromegaly, H1 2016 10
Number of Products under Development for Acromegaly - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Acromegaly - Pipeline by Aegis Therapeutics, LLC, H1 2016 19
Acromegaly - Pipeline by Antisense Therapeutics Limited, H1 2016 20
Acromegaly - Pipeline by Chiasma, Inc., H1 2016 21
Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 22
Acromegaly - Pipeline by DexTech Medical AB, H1 2016 23
Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 24
Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 25
Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 26
Acromegaly - Pipeline by Ipsen S.A., H1 2016 27
Acromegaly - Pipeline by Italfarmaco S.p.A., H1 2016 28
Acromegaly - Pipeline by Novartis AG, H1 2016 29
Acromegaly - Pipeline by Peptron, Inc., H1 2016 30
Acromegaly - Pipeline by Sompharmaceuticals S.A., H1 2016 31
Acromegaly - Pipeline by Strongbridge Biopharma plc , H1 2016 32
Assessment by Monotherapy Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 37
Number of Products by Stage and Route of Administration, H1 2016 39
Number of Products by Stage and Molecule Type, H1 2016 41
Acromegaly Therapeutics - Recent Pipeline Updates, H1 2016 68
Acromegaly - Dormant Projects, H1 2016 79
Acromegaly - Discontinued Products, H1 2016 80